PACT Pharma Highlights Capabilities and Versatility of Novel Non-Viral Gene Editing Technology in Presentation at American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting – PR Newswire

Searching for your content…
In-Language News
Contact Us
888-776-0942
from 8 AM – 10 PM ET
News provided by
May 16, 2022, 07:00 ET
Share this article
Highly Versatile PACT^NV Non-Viral Gene Editing Platform Demonstrates Ability to Knock-Out, Knock-Down, Knock-In and Precisely Regulate Target Genes in Single Step
Technology Has Potential to Expand the Applicability of T Cell-Based Therapeutics and Other Cellular Therapies
SOUTH SAN FRANCISCO, Calif., May 16, 2022 /PRNewswire/ — PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoantigen-specific T cell receptor (neoTCR) T cell therapies for the eradication of solid tumors, today announced that new data on PACT^NV, the company’s non-viral precision gene editing technology, were highlighted in a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting. Presented findings demonstrated the potential of the PACT^NV technology to enhance the functionality and applicability of T cell-based therapeutics, as well as other cellular therapies, through targeted gene editing. Specifically, researchers showed the ability of the versatile platform to knock-out, knock-down, knock-in and precisely regulate target genes in a single step to achieve desired activity for its neoTCR T cells. The ASGCT conference is being held May 16-19, 2022, in Washington, D.C.
The poster presentation reported research findings by PACT scientists demonstrating the ability to utilize the company’s PACT^NV technology to generate TCR T cells in a single step. In creating these novel patient-specific neoTCR T cells, PACT highlighted the following capabilities of its gene editing platform:
"Taken together, the powerful gene editing capabilities possessed by our PACT^NV platform offer the potential to expand the applicability of T cell therapeutics, while extending the potential use of the technology to other cellular therapies," said Stefanie Mandl, Ph.D., senior vice president, head of research at PACT Pharma. "We are particularly excited about the versatility to add, eliminate and/or precisely modulate multiple genes within our neoTCR T cells to create novel, personalized therapeutic candidates with the potential to address a range of solid tumors. We look forward to continuing our research and development efforts in support of our PACT^NV technology, while continuing our ongoing Phase 1 clinical trial of non-viral PACT^NV gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors."
PACT is currently conducting a Phase 1 clinical trial evaluating the safety, tolerability and feasibility of adoptive cell therapy with its non-viral PACT^NV gene-edited autologous neoTCR T cells in advanced and metastatic solid tumors. This trial, in combination with extensive preclinical studies, has provided the company with unique data sets and insights derived from the core technologies that comprise its personalized adoptive T cell therapy platform for the treatment of solid tumors.
A copy of the poster presented at the ASGCT conference is available on the "Events" page of the PACT Pharma website at: https://www.pactpharma.com/news/?filter=events.
About PACT Pharma, Inc.
PACT is a clinical-stage biopharmaceutical company pioneering individualized, non-viral precision genome engineered, tumor-specific T cell therapies for the treatment of patients with solid cancers. PACT is now enrolling patients in its first-in-human Phase 1 clinical trial.
Each person’s cancer emerges with a private signature of mutations. PACT identifies these cancer mutation targets (neoantigens) for each person, biochemically verifies and captures T cells from their blood and uses its proprietary, non-viral precision genome engineering technologies to manufacture a personalized immune cell therapy product for each person with cancer.
For more information, please visit www.pactpharma.com.
Contacts:
PACT Pharma
Atulya Agarwal
[email protected]
Vida Strategic Partners (on behalf of PACT Pharma)
Tim Brons (Media)
415-675-7402
[email protected]
SOURCE PACT Pharma
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET

source

Share:

More Posts

Market Research

Pulse Surveys

Turn feedback into action

Our survey platform makes it easy to measure and understand feedback so you can drive growth and innovation

Pulse Handshak

Pulse Handshak

Collaborative online survey tool for the market research industry. Remote assisted surveying just like face-to-face interviews. Here interviewers can talk to the respondent over the web-console without the need for any other communication channel and share the same Q're with responses and click actions.

Pulse FE

Pulse FE

Pulse Field Expert or Pulse FE is the main platform for both offline and online survey at softofficepro.com. It is robust and used by hundreds of clients over tens of years with millions of responses. Do it once Q're and deploy on both offline devices (android) and online forms makes it a great cost effective platform for any kind of responses

Pulse Ultimate

Pulse Ultimate

Pulse Ultimate is targeted for tracking studies and retail audits. An offline survey system offering extreme field control including processes like data quality check, back-check, rework, comparison with previous wave data etc. helps to get the best results on a day-to-day basis

Pulse LS

Pulse LS

Use a managed Limesurvey and our expertise for creating complex forms and token based user management. Use optional mailing system to send survey invitation to each participant and track progress of the response status. Industry standard SPSS / R output supported